INHALED ANESTHETIC AGENT THERAPY AND DELIVERY SYSTEM

(19)

(11)

EP 2 403 576 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.06.2014 Bulletin 2014/23

(45)	Mention of the grant of the patent:
	09.04.2014 Bulletin 2014/15

(21)	Application number: 10705035.3

(22)	Date of filing: 09.02.2010

(51)

International Patent Classification (IPC):

A61M 16/10^(2006.01)

A61M 16/18^(2006.01)

(86)	International application number:
	PCT/US2010/023551

(87)	International publication number:
	WO 2010/096299 (26.08.2010 Gazette 2010/34)

(54)	INHALED ANESTHETIC AGENT THERAPY AND DELIVERY SYSTEM NARKOSEMITTEL-INHALATIONSBEHANDLUNG UND ABGABESYSTEM THERAPIE PAR AGENT ANESTHESIQUE INHALE ET SYSTEME D'ADMINISTRATION

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

20.02.2009 US 389802

(43)	Date of publication of application:
	11.01.2012 Bulletin 2012/02

(73)	Proprietors:
	Baxter International Inc. Deerfield, IL 60015 (US) Baxter Healthcare SA 8152 Glattpark (Opfikon) (CH)

(72)	Inventors:
	FLANAGAN, Craig, T. New York NY 10011 (US) HURST, William, S. Burlington WI 53105-7781 (US) SHEU, Lien-lung Berkley Heights NJ 07922 (US) BLOCK, Thomas, A. Lake Bluff IL 60044 (US) WU, Haiming North Attleboro MA 02760 (US)

(74)	Representative: Potter Clarkson LLP
	The Belgrave Centre Talbot Street Nottingham, NG1 5GG Nottingham, NG1 5GG (GB)

(56)

References cited: :

WO-A1-01/07108
DE-C1- 10 106 010
GB-A- 2 254 005
US-A1- 2006 225 735

WO-A1-03/090826
GB-A- 300 444
US-A- 3 941 573

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).